This company listing is no longer active
Ectin Research Past Earnings Performance
Past criteria checks 0/6
Ectin Research's earnings have been declining at an average annual rate of -29.3%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been declining at an average rate of 84.5% per year.
Key information
-29.3%
Earnings growth rate
-24.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 30.5% |
| Revenue growth rate | -84.5% |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Ectin Research makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -18 | 9 | 0 |
| 31 Mar 24 | 0 | -17 | 8 | 0 |
| 31 Dec 23 | 0 | -17 | 8 | 0 |
| 30 Sep 23 | 0 | -9 | -1 | 0 |
| 30 Jun 23 | 0 | -12 | 1 | 0 |
| 31 Mar 23 | 0 | -14 | 14 | 0 |
| 31 Dec 22 | 0 | -13 | 13 | 0 |
| 30 Sep 22 | 0 | -12 | 4 | 0 |
| 30 Jun 22 | 0 | -13 | 5 | 0 |
| 31 Mar 22 | 0 | -12 | 4 | 0 |
| 31 Dec 21 | 1 | -12 | 1 | 0 |
| 31 Aug 20 | 2 | -1 | 0 | 0 |
| 31 Aug 19 | 1 | -1 | 0 | 0 |
| 31 Aug 18 | 1 | 0 | 0 | 0 |
Quality Earnings: ECTIN B is currently unprofitable.
Growing Profit Margin: ECTIN B is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ECTIN B is unprofitable, and losses have increased over the past 5 years at a rate of 29.3% per year.
Accelerating Growth: Unable to compare ECTIN B's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ECTIN B is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (4.3%).
Return on Equity
High ROE: ECTIN B's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.